Geron Corporation Common Stock (GERN)
Stock · NASDAQ · Health Care
$1.18as of 10/16/2026
Price chart
Active signals
GERN Signal Track Record
How signals performed across all stocks →What GERN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +4.7% | 56% | September 18, 2026 |
| Bollinger Band Breakdown | 26 | +2.0% | 62% | September 9, 2026 |
| Bollinger Band Breakout | 23 | -0.2% | 48% | August 5, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +7.8% | 67% | July 29, 2026 |
| Any 20-session window (baseline) | -0.9% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplasti…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 258
- Website
- www.geron.com/
Fundamentals
- 1-day range
- $1.2$1.24
- Market cap
- $1.01B
- P/E (trailing)
- —
- P/E (forward)
- 30.75
- EPS (trailing)
- $-0.10
- Dividend yield
- —
- Beta
- 0.57
- Avg. volume
- 9.87M
How Geron Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Geron Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- JANXJanux Therapeutics Inc. Common Stock$16.51▼ 4.68%Market cap $981.85MP/E —$12.12$35.34
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| JANX Janux Therapeutics Inc. Common Stock | $981.85M | — | $16.51 | ▼ 4.68% | $12.12$35.34 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Geron Q2 2026 Earnings Call: Complete Transcriptbenzinga · 10/8/2026
- Geron Q2 2026 Earnings Call: Complete TranscriptBenzinga · 10/8/2026
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Yahoo · 10/7/2026
- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/18/2026
- Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption ExpandsYahoo · 9/16/2026
- Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use ExpandsYahoo · 9/13/2026
Insider Activity
Insider Actions →- Robert J. Spiegel · September 30, 2026 · Grant6.4K @ $1.23
- Robert J. Spiegel · June 30, 2026 · Grant6.1K @ $1.28
- Elizabeth G. O'Farrell · May 20, 2026 · Grant220.0K
- Bir Dawn Carter · May 20, 2026 · Grant220.0K
- Molineaux Susan · May 20, 2026 · Grant220.0K
- Robert J. Spiegel · May 20, 2026 · Grant220.0K
- McDonald John F · May 20, 2026 · Grant220.0K
- Timothy Williams · April 13, 2026 · Grant2.50M
Institutional Ownership
March 31, 2026
- Total shares held
- 489.41M
- Total value held
- $725.47M
- Institutional holders
- 247
- Unknown63.77M
- Unknown47.32M
- Unknown41.51M
- Unknown31.72M
- Unknown30.50M
- Unknown26.67M
- Unknown22.11M
- Unknown20.46M
- Unknown19.62M
- Unknown18.83M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses
Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.